Menu
Search
|

Menu

Close
X

Merus NV MRUS.OQ (NASDAQ Stock Exchange Global Market)

23.78 USD
-0.71 (-2.90%)
As of Jul 19
chart
Previous Close 24.49
Open 24.49
Volume 4,346
3m Avg Volume 10,969
Today’s High 24.49
Today’s Low 23.78
52 Week High 26.49
52 Week Low 13.34
Shares Outstanding (mil) 22.62
Market Capitalization (mil) 551.05
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, EUR)
FY17
14
FY16
3
FY15
1
EPS (EUR)
FY17
-4.165
FY16
-1.073
FY15
-1.237
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.86
Price to Sales (TTM)
vs sector
34.82
8.16
Price to Book (MRQ)
vs sector
8.52
4.20
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
0.00
17.38
LT Debt to Equity (MRQ)
vs sector
0.00
13.24
Return on Investment (TTM)
vs sector
-60.25
13.13
Return on Equity (TTM)
vs sector
-178.45
15.07

EXECUTIVE LEADERSHIP

Mark Iwicki
Chairman of the Supervisory Board, Since
Salary: --
Bonus: --
Ton Logtenberg
Chief Executive Officer, Since
Salary: --
Bonus: --
John Crowley
Chief Financial Officer, Executive Vice President, Since 2016
Salary: --
Bonus: --
Shelley Margetson
Chief Operating Officer, Executive Vice President, Since 2016
Salary: --
Bonus: --
John de Kruif
Chief Technology Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Yalelaan 62
UTRECHT     3584 CM

Phone: +3130.2538800

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

SPONSORED STORIES